AZYO Aziyo Biologics

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:  

Webcast:

U.S. Investors: 877-407-8029

International Investors: 201-689-8029

Conference ID: 13742087

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at .

About Elutia

Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners

 



EN
06/11/2023

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Millio...

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financ...

43m 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Report Third Quarter 2025 Financial Results on Thursday, Nov...

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

October 23, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday...

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21, 2025Presentation Time: 1:00 p.m. PT (4:00 p.m. ET)Webcast:  Elutia management will also...

October 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board o...

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels’ appointment, W. Matthew Zuga and Maybelle Jordan have bo...

October 10, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scient...

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporatio...

October 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch